Zynex Inc

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. The company was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Zynex Inc (ZYXI) achieves record highs in Q4 2022

Zynex Inc (ZYXI) delivered strong financial performance in Q4 2022 and full-year 2022, projecting continued growth in 2023. The company's focus on innovation, regulatory milestones, and operational efficiency positions it well for future success.

Zynex Inc reports robust Q1 earnings, eyes revenue growth

Zynex Inc's Q1 2023 performance reflects strong revenue growth and increased orders, supported by strategic initiatives like stock buybacks.
While facing challenges in scaling the sales force and navigating market dynamics, the company is well-positioned to leverage opportunities for expansion and innovation.
Investors can look forward to continued revenue growth, product development, and potential market expansion as Zynex pursues its growth targets.

Zynex Inc reports record revenue and FDA clearances, reaffirms guidance

Zynex Inc delivered robust financial results in Q2 2023, showcasing consistent profitability and revenue growth across its divisions.
The company's focus on product innovation, FDA clearances, and strategic financial moves underscores its commitment to sustained growth and market leadership.
While facing potential challenges, Zynex Inc remains optimistic about its future outlook, aiming to capitalize on market opportunities and drive continued success.

Zynex reports record revenue and growth outlook, driven by innovation

Zynex Inc (ZYXI) delivered strong financial results in Q3 2023, driven by revenue growth, operational efficiency, and strategic product innovations.
The company's focus on noninvasive pain management solutions and commitment to regulatory milestones underscore its growth potential and market positioning.
While facing challenges such as market competition and operational scalability, Zynex's strengths in financial performance and innovation present opportunities for sustained success.

Zynex Inc (ZYXI) reports record revenue and explores strategic alternatives

Zynex Inc (ZYXI) delivered a strong performance in 2023, marked by record revenue, profitability, and operational achievements, positioning the company for continued growth and success.
While facing challenges related to strategic decision-making and operational execution, Zynex remains well-positioned to capitalize on opportunities for revenue expansion, product innovation, and market leadership.
With a focus on financial stability, product diversification, and strategic growth initiatives, Zynex is poised to navigate challenges, leverage opportunities, and drive value for shareholders in the upcoming year.

Zynex Inc reports revenue growth and FDA clearance success

Zynex Inc (ZYXI) demonstrated solid financial performance in Q1 2024, with revenue growth and positive cash flow.
The company's focus on product innovation, sales expansion, and revenue diversification positions it well for future growth.
While facing challenges such as revenue delays and strategic uncertainties, Zynex remains optimistic about its growth prospects and market opportunities.

Zynex Inc reports strong Q2 performance, eyes $200M revenue target

Zynex Inc delivered a strong Q2 2024 performance with revenue growth, improved sales efficiency, and a positive outlook for the year, targeting $200 million in total revenue.
While facing challenges in revenue diversification and sales force refinement, Zynex maintains a solid gross profit margin and a focus on operational excellence.
The company's Monitoring Solutions division shows promise, with ongoing product milestones and plans for FDA submission, indicating future growth potential and market expansion.
Strategic management of challenges and capitalizing on opportunities position Zynex well for sustained growth and profitability in the evolving healthcare market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. It also develops a new blood volume monitor for use in hospitals and surgery centers. The company was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

Zynex, Inc. (NASDAQ:ZYXI ) Q1 2023 Earnings Conference Call April 27, 2023 4:15 PM ET Company Participants Louisa Smith - Investor Relations Thomas Sandgaard - Chairman, President and Chief Executive Officer Anna Lucsok - Chief Operating Officer Donald Gregg - Vice President, Zynex Monitoring Solutions Daniel Moorhead - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Adam Maeder - Piper Sandler Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Zynex First Quarter 2023 Earnings Conference Call.

Zynex, Inc. (ZYXI) Q1 2023 Earnings Call Transcript

Hackett Group

nLIGHT Inc

Pulmonx

Gambling.com Group

Hudson Technologies

Solid Power

Though common sense tells us to load up on securities with established track records, the concept of Nasdaq small-cap stocks to buy invariably delivers enticement. To be sure, there's nothing wrong with riding the blue chips to a secure future.

7 Nasdaq Small-Cap Stocks Set to Outperform in 2023

Zynex Inc. (ZYXI) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.03 per share a year ago.

Zynex Inc. (ZYXI) Beats Q1 Earnings and Revenue Estimates

ENGLEWOOD, Colo. , April 27, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the first quarter ended March 31, 2023.

Zynex Announces 2023 First Quarter Earnings

Carriage Services

Karat Packaging

REX American Resources

Cambium Networks Corp

VAALCO Energy

Tremor International Ltd

Although larger-capitalization companies typically offer the greatest probability of success, for outright upside magnitude, the most potential often lies with small-cap stocks to buy. Let's use baseball terms to set up the framework.

7 Small-Cap Stocks With Big Potential

ENGLEWOOD, Colo. , April 19, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will report first quarter 2023 financial results on Thursday, April 27, 2023.

Zynex, Inc. to Announce First Quarter 2023 Financial Results

Zynex: Seems An Odd Short Target

ENGLEWOOD, Colo. , April 11, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced preliminary results for first quarter 2023 and reiterated full year guidance.

Zynex Reports Preliminary First Quarter 2023 Results

ENGLEWOOD, Colo. , April 6, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has been ranked 191 out of 500 on The Financial Times fourth annual list of The Americas' Fastest Growing Companies 2023.

Zynex Earns Spot on Financial Times List of "The Americas' Fastest-Growing Companies 2023" for Second Consecutive Year

NEW YORK , April 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zynex, Inc. - ZYXI

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) on behalf of Zynex stockholders. Our investigation concerns whether Zynex has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action.

ZYNEX ALERT: Bragar Eagel & Squire, P.C. is Investigating Zynex, Inc. on Behalf of Zynex Stockholders and Encourages Investors to Contact the Firm

NEW YORK , March 30, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Zynex, Inc. (NASDAQ: ZYXI) resulting from allegations that Zynex may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Zynex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING NATIONAL FIRM, Encourages Zynex, Inc. Investors to Inquire About Class Action Investigation - ZYXI

NEW YORK--(BUSINESS WIRE)---- $ZYXI #classaction--The law firm of Kirby McInerney LLP is investigating potential claims against Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI). The investigation concerns whether Zynex and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. Zynex, through its subsidiary, markets electro therapy products, which help improve the quality of life of patients who have functional disabilities.

Kirby McInerney LLP Continues Investigation of Shareholder Claims Against Zynex, Inc. (ZYXI)

ENGLEWOOD, Colo. , March 21, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the Denver Business Journal has ranked Zynex sixth in a list of the largest Denver-area Biotechnology/Bioscience companies, according to the number of full-time employees (FTEs).

Zynex Included in Denver-Area's Top 10 Biotechnology/Bioscience Companies

NEW YORK , March 14, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zynex, Inc. (NASDAQ: ZYXI) resulting from allegations that Zynex may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Zynex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Zynex, Inc. Investors with Losses to Inquire About Class Action Investigation - ZYXI

Zynex Inc shares soared after the company posted fourth quarter earnings and revenue that beat Wall Street analyst estimates. For the period ended December 31, 2022, the Englewood, Colorado-based medical device manufacturer reported earnings of $0.20 per share on revenue of $48.8 million.

Zynex soars after 4Q earnings and revenue beat Street estimates

Zynex, Inc. (NASDAQ:ZYXI ) Q4 2022 Earnings Conference Call March 13, 2023 8:30 AM ET Company Participants Louisa Smith - Investor Relations Thomas Sandgaard - Chairman, President and Chief Executive Officer Dan Moorhead - Chief Financial Officer Anna Lucsok - Chief Operating Officer Donald Gregg - Vice President, Zynex Monitoring Solutions Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Simran Kaur - Piper Sandler Yi Chen - H.C. Wainwright Operator Good morning, ladies and gentlemen and welcome to the Zynex Fourth Quarter 2022 Earnings Conference Call.

Zynex, Inc. (ZYXI) Q4 2022 Earnings Call Transcript

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 5.26% and 1.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zynex Inc. (ZYXI) Q4 Earnings Surpass Estimates

ENGLEWOOD, Colo. , March 13, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the fourth quarter and full year ended December 31, 2022.

Zynex Announces 2022 Fourth Quarter and Full Year Earnings

LOS ANGELES, CA / ACCESSWIRE / March 12, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zynex, Inc. ("Zynex" or "the Company") (NASDAQ:ZYXI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zynex, Inc. and Encourages Investors with Losses to Contact the Firm

ENGLEWOOD, Colo. , March 10, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI) , an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will report fourth quarter  and full-year 2022 financial results on Monday, March 13, 2023.

Zynex, Inc. Reschedules Release of Fourth Quarter and Full Year 2022 Financial Results

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zynex, Inc. (NASDAQ: ZYXI) resulting from allegations that Zynex may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Zynex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Zynex, Inc. Investors with Losses in Excess of $100K to Inquire About Class Action Investigation – ZYXI

LOS ANGELES--(BUSINESS WIRE)---- $ZYXI #ZYXI--The Schall Law Firm Announces it is Investigating Claims Against Zynex, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zynex, Inc. and Encourages Investors with Losses to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zynex, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) investors concerning the Company's possible violations of the federal securities laws.

News for Zynex Inc Stock (ZYXI)